

Drigard & Castro
Abogados

SUPERINDUSTRIA Y COMERCIO
Radiacion 00058796 00000004 folios 11
Fecha (AMB) 2003-05-22 17 30 06
Tramite : 002 PATENTES 3 1 REGISTRO/ 329 COMPLETO
Dependencia 2820 DIVISION DE NUEVAS CREACIONES

Apartado 3692

Cra 7 16 56
Bogotá Colombia S A

Tel Conn 3802200
Tel/Fax (57 1) 2827976
(57 1) 3802700

E Mail bricas@brigardycastro.com.co

AS 04 397

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES
E S D

REF Expediente No 00 058 796 - Solicitud de Patente
a favor de AstraZeneca AB

Titulada COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE EL
INHIBIDOR HMG CoA REDUCTASA Y UNA SAL TRIBÁSICA
DE FOSFATO

RAMIRO CASTRO DUQUE, vecino de Bogotá, portador de la tarjeta profesional No 1003, obrando como apoderado de la Sociedad AstraZeneca AB, según lo acredita el documento de Poder presentado en esa División, me permito anexar al presente escrito los siguientes documentos

- 1 Copia de la correspondiente de la solicitud Europea No 1 223 918 B1, concedida por la Oficina Europea de Patentes

De la señora jefe atentamente,



RAMIRO CASTRO DUQUE
C C No 170 322 de Bogotá
Código 340
Cra 7a No 16-56 Piso 9

Bogotá, Mayo 22, 2003
CPB/hsr

4397
D
68
65

(18)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets


(11) **EP 1 223 918 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent 05.02.2003 Bulletin 2003/06	(51) Int Cl 7 A61K 9/20, A61K 31/505
(21) Application number 00953283 9	(86) International application number PCT/GB00/03014
(22) Date of filing 04.06 2000	(87) International publication number WO 01/054668 (02 08 2001 Gazette 2001/31)

(54) **PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG COA REDUCTASE INHIBITOR**
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND EIN HMG COA REDUCTASE INHIBITOR
COMPOSITIONS PHARMACEUTIQUES RENFERMANT UN INHIBITEUR DE LA HMG REDUCTASE

(84) Designated Contracting States AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE Designated Extension States AL LT LV MK RO SI (30) Priority 28 01 2000 GB 0001621 (43) Date of publication of application 24.07.2002 Bulletin 2002/30 (73) Proprietor AstraZeneca AB 161 85 Södertälje (SE)	(72) Inventors • CREEKMORE, Joseph, Richard Wilmington DE 19850-5437 (US) • WIGGINS Norman Alfred Wilmington, DE 19850-5437 (US) (56) References cited EP-A- 0 521 471 GB-A- 2 282 229 • GRAUL A ET AL "ZO-4522 Hypolipidemic HMG-CoA reductase inhibitor DRUGS OF THE FUTURE vol 24, no 8, May 1999 (1999-05), pages 511-513, XP000882032 ISSN 0377-8282
---	--

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art 99(1) European Patent Convention)

EP 1 223 918 B1

69
766

Description

[0001] The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing (E)-7-[4-(4-fluorophenyl)-8-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-8-enoic acid or a pharmaceutically acceptable salt thereof (and referred to hereinafter as "the Agent"), in particular the sodium and calcium salts, and especially the calcium salt bis[(E)-7-[4-(4-fluorophenyl)-8-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-8-enoic acid] calcium salt (of the formula I hereinafter)

[0002] The Agent is disclosed as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG CoA reductase) in European Patent Application Publication No. 0521471 and in Bioorganic and Medicinal Chemistry (1987) 5(2) 437-444 and is useful in the treatment of hypercholesterolemia, hyperlipidproteinemia and atherosclerosis.

[0003] A problem associated with the Agent is that it undergoes degradation under certain conditions. This makes it difficult to formulate the product and provide a pharmaceutical composition with adequate storage life. The major degradation products formed are the corresponding (3R,5S) lactone (hereinafter referred to as "the lactone") and an oxidation product (hereinafter referred to as "B2") in which the hydroxy group adjacent to the carbon-carbon double bond is oxidised to a ketone functionality.

[0004] It is therefore important to find a pharmaceutical composition of the Agent which remains stable over a prolonged period. It is also preferable that such a composition has a good flow rate to assist processing into unit dosage forms for oral administration, for example into tablets, and good disintegration and dissolution characteristics when processed into tablets for oral administration, which tablets can be in different dosage strengths. It is also desirable that such tablets are of a convenient size for ease of administration.

[0005] Pharmaceutical formulations of certain 7-substituted-3,5-dihydroxy-8-heptenoic acid salts, which are HMG CoA reductase inhibitors, are disclosed in UK Patent 2282229. These formulations require the presence of an alkaline medium (such as a carbonate or bicarbonate) capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.

[0006] We have now discovered a novel pharmaceutical composition of the Agent which has advantageous properties and which solves one or more of the problems associated with formulation of the Agent.

[0007] Accordingly, a first aspect of the invention comprises a pharmaceutical composition comprising the Agent and a tribasic phosphate salt in which the cation is multivalent.

[0008] A second aspect of the invention comprises the use of a tribasic phosphate salt in which the cation is multivalent to stabilise the Agent.

[0009] A tribasic phosphate salt in which the cation is multivalent includes, for example, tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate. Tribasic calcium phosphate is especially preferred.

[0010] The ratio of tribasic phosphate salt to Agent in the pharmaceutical composition is, for example, within the range of 1:80 to 50:1 by weight, for example 1:50 to 50:1 by weight, such as 1:10 to 10:1 by weight, and more particularly 1:5 to 10:1 by weight.

[0011] Preferably the pharmaceutical composition of the invention is formulated into an oral dosage form, such as a tablet. Accordingly, a further aspect of the invention comprises a pharmaceutical composition comprising the Agent, a tribasic phosphate salt in which the cation is multivalent, and one or more fillers, binders, disintegrants or lubricants.

[0012] A still further aspect of the invention relates to a pharmaceutical composition for oral administration comprising the Agent, one or more fillers, one or more binders, one or more disintegrants, one or more lubricants and a tribasic phosphate salt in which the cation is multivalent.

[0013] Suitable fillers include, for example, lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g. microcrystalline cellulose, cellulose), calcium sulfate, xylitol and lactitol.

[0014] Suitable binders include, for example, polyvinylpyrrolidone, lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatin and sodium alginate.

[0015] Suitable disintegrants include, for example, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycolate, corn starch, microcrystalline cellulose, hydroxypropyl methylcellulose and hydroxypropyl cellulose.

[0016] Suitable lubricants include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hydrogenated vegetable oils, mineral oil, polyethylene glycols and sodium stearyl fumarate.

[0017] Additional conventional excipients which may be added include preservatives, stabilisers, anti-oxidants, silica flow conditioners, antilatherants or glidants.

[0018] Other suitable fillers, binders, disintegrants, lubricants and additional excipients which may be used are described in *Handbook of Pharmaceutical Excipients*, 2nd Edition, American Pharmaceutical Association; *The Theory and Practice of Industrial Pharmacy*, 2nd Edition, Lachman, Leon, 1978; *Pharmaceutical Dosage Forms, Tablets Vol-*

470
67

urne 1 2nd Edition Lieberman Hebert A et al 1989 *Modern Pharmaceutics*, Banker Gilbert and Rhodes Christopher T 1979 and *Remington's Pharmaceutical Sciences*, 15th Edition 1975

[0018] Typically the Agent will be present in an amount within the range of 1 to 50% and preferably from 1 to 20% (especially 2 to 15%) by weight of the composition

[0019] Typically the tribasic phosphate salt such as tribasic calcium phosphate will be present in an amount within the range of 1 to 50% for example 1 to 25%, such as 1 to 20% and particularly 5 to 18% by weight

[0020] Typically one or more fillers will be present in an amount 30 to 90% by weight

[0021] Typically one or more binders will be present in an amount 2 to 90% by weight.

[0022] Typically one or more disintegrants will be present in an amount 2 to 10% and especially 4 to 6% by weight

[0023] It will be appreciated that a particular excipient may act as both a binder and a filler or as a binder a filler and a disintegrant. Typically the combined amount of filler binder and disintegrant comprises for example 70 to 90% by weight of the composition

[0024] Typically one or more lubricants will be present in an amount 0.5 to 3% and especially 1 to 2% by weight.

[0025] Preferred compositions of the invention include for example those comprising the Agent tribasic calcium phosphate and excipients selected from lactose mannitol microcrystalline cellulose, povidone crospovidone sodium starch glycolate and magnesium stearate. Preferred independent compositions of the invention include for example compositions comprising the Agent, tribasic calcium phosphate microcrystalline cellulose lactose, sodium starch glycolate butylated hydroxytoluene and magnesium stearate compositions comprising the Agent povidone, tribasic calcium phosphate microcrystalline cellulose mannitol sodium starch glycolate butylated hydroxytoluene and magnesium stearate compositions comprising the Agent tribasic calcium phosphate crospovidone microcrystalline cellulose lactose and magnesium stearate and compositions comprising the Agent, povidone tribasic calcium phosphate microcrystalline cellulose lactose sodium starch glycolate magnesium stearate and butylated hydroxytoluene. Where lactose and microcrystalline cellulose are used these are preferably present in the ratio of about 1:1 to 3:1 by weight

[0026] Compositions of the invention which are of particular interest include for example the specific embodiments set out hereinafter in the accompanying Examples

[0027] The pharmaceutical composition of the invention may be prepared using standard techniques and manufacturing processes generally known in the art for example by dry blending the components. For example the Agent, the tribasic phosphate salt (for example tribasic calcium phosphate) one or more fillers, one or more binders and one or more disintegrants as well as other additional excipients if desired are blended together. The components of the blend prior to blending or the blend itself may be passed through a mesh screen for example a 400-700 μ m mesh screen. A lubricant which may also be screened is then added to the blend and blending continued until a homogeneous mixture is obtained. The mixture is then compressed into tablets. Alternatively a wet granulation technique can be employed. For example the Agent the tribasic phosphate salt one or more fillers one or more binders and a portion of a disintegrant, as well as other additional excipients if desired are blended together, for example by using a granulator, and the powder blend is granulated with a small volume of purified water. The granulate is dried and passed through a mill. The remainder of the disintegrant and a lubricant are added to the milled granulation and after blending the resultant homogeneous mixture is compressed into tablets. It will be appreciated that modifications of the dry blending and wet granulation techniques including the order of addition of the components and their screening and blending prior to compression into tablets may be carried out according to principles well known in the art.

[0028] A tablet coating may then be applied for example by spray-coating with a water based film coating formulation. The coating may comprise, for example lactose, hydroxypropyl methylcellulose triacetin titanium dioxide and ferric oxides. Coating ingredient combinations are commercially available such as those described in the Examples hereinafter. The coating may comprise for example 0.5 to 10% by weight of the tablet composition particularly 1 to 6% and preferably 2 to 3%. Coatings containing ferric oxides are especially preferred as they reduce the rate of formation of photodegradation products of the Agent.

[0029] A further aspect of the present invention comprises a method of preparing a stabilised pharmaceutical composition which comprises admixing the Agent with a tribasic phosphate salt in which the cation is multivalent. A further aspect of the present invention comprises a method of producing a stabilised pharmaceutical composition which comprises incorporating a tribasic phosphate salt in which the cation is multivalent in a pharmaceutical composition containing the Agent.

[0030] The following pharmaceutical compositions wherein the Agent is the calcium salt of formula I are intended to illustrate the invention without being limitative in any way

68
H

Example 1

[0031]

5

10

The Agent	2 50 mg
Tribasic calcium phosphate	20 0 mg
Microcrystalline cellulose	47 0 mg
Lactose monohydrate	47 0 mg
Sodium starch glycolate	3 00 mg
Butylated hydroxytoluene	0 05 mg
Magnesium stearate	1 00 mg

15

[0032] The Agent microcrystalline cellulose lactose monohydrate sodium starch glycolate tribasic calcium phosphate and butylated hydroxytoluene were blended together for 10 minutes Magnesium stearate was screened through a #40 mesh (425 μ m) screen and added to the blend and blending continued for a further three minutes The resulting homogeneous mixture was compressed into tablets

20

[0033] The tablets were stored at 70°C/80% relative humidity for one week After one week there was found to be only 0 11 %w/w of the oxidation product B2 formed and only 0 50%w/w of the lactone By comparison a similar formulation in which 20 0 mg of tribasic calcium phosphate was replaced by 20 0 mg of dibasic calcium phosphate 0 23%w/w of B2 was formed and 15 61%w/w of the lactone

Example 2

25

[0034]

30

35

The Agent	2 50 mg
Povidone	2 50 mg
Tribasic calcium phosphate	20 0 mg
Microcrystalline cellulose	47 0 mg
Mannitol	47 0 mg
Sodium starch glycolate	3 00 mg
Butylated hydroxytoluene	0 05 mg
Magnesium stearate	1 00 mg

40

[0035] The Agent, povidone mannitol microcrystalline cellulose butylated hydroxytoluene tribasic calcium phosphate and sodium starch glycolate (in the amounts given above) were blended for 5 to 80 minutes Magnesium stearate was screened through a #40 mesh (425 μ m) screen and added to the blend and blending continued for a further three minutes The resulting homogeneous mixture was compressed into tablets The compressed tablets were coated by spraying with a mixture of hydroxypropyl methylcellulose polyethylene glycol 400 titanium dioxide and ferric oxide (sold as Spectrablend by Warner-Jenkinson) and water in a coating pan The weight gain provided by the coating was 1 to 8%w/w and preferably 2 to 3 %w/w

45

[0036] The tablets were stored at 70°C/80% relative humidity for one week After one week there was found to be only 0 08%w/w of the oxidation product B2 formed and only 2 22%w/w of the lactone

Example 3

[0037]

50

55

The Agent	2 60 mg
Croscapvidone	3 75 mg
Tribasic calcium phosphate	5 68 mg
Microcrystalline cellulose	15 5 mg
Lactose monohydrate	46 5 mg
Magnesium stearate	0 94 mg

69
69 7K

EP 1 223 918 B1

[0038] The Agent and crospovidone were blended together for 5 minutes and the blend then passed through a 400-700um screen. A small portion of the microcrystalline cellulose was passed through the screen afterwards. The screened material was blended with the other ingredients excluding the lubricant for 10 minutes. Magnesium stearate was passed through a #40 mesh (425 um) screen and added to the blend and the mixture was blended for a further 3 minutes. The resulting homogeneous mixture was compressed into tablets. The compressed tablets were coated by spraying with a mixture of lactose monohydrate, hydroxypropyl methylcellulose, triacetin and ferric oxide (sold as Opa dry II by Colorcon) and water in a coating pan. The weight gain provided by the coating 1 to 6%w/w and preferably 2 to 3%w/w.

[0039] The tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.19%w/w of the oxidation product B2 had formed and only 2.71%w/w of the lactone.


Example 4

[0040]

The Agent	2.50 mg
Povidone	2.50 mg
Tribasic calcium phosphate	20.0 mg
Microcrystalline cellulose	34.5 mg
Lactose monohydrate	34.0 mg
Sodium starch glycolate	8.00 mg
Magnesium stearate	1.00 mg
Butylated hydroxytoluene	0.05 mg

[0041] A portion of the tribasic calcium phosphate and butylated hydroxytoluene were blended for 30 seconds in a bag. The Agent, povidone, remainder of the tribasic calcium phosphate, microcrystalline cellulose, lactose monohydrate, tribasic calcium phosphate/butylated hydroxytoluene mixture and a portion of the sodium starch glycolate were blended in a granulator for 30 seconds. The powder blend was granulated with purified water for 1 minute at the addition rate of 70 mg/tablet/minute. The granulation is dried in a fluidized bed drier at 50°C until the loss on drying is less than 2% w/w. The dried granulation is passed through a mill (e.g. Comil). The milled granulation and the remainder of the sodium starch glycolate was blended for approximately 5 minutes. Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes. The resulting homogeneous mixture was compressed into tablets.

[0042] The tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.23 %w/w of the oxidation product B2 had formed and only 0.28%w/w of the lactone. By comparison a similar formulation in which 20.0 mg of tribasic calcium phosphate was replaced by 20.0 mg of dibasic calcium phosphate 0.19 %w/w of B2 was formed and 28.15 %w/w of the lactone.



Formula I

70 73
X

Claims

- 1 A pharmaceutical composition comprising (E) 7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl(methylsulfonyl)amino}pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient and a tribasic phosphate salt in which the cation is multivalent
- 2 A pharmaceutical composition as claimed in claim 1 wherein the tribasic phosphate salt in which the cation is multivalent is selected from tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate
- 3 A pharmaceutical composition as claimed in claim 1 or 2 wherein the tribasic phosphate salt in which the cation is multivalent is tribasic calcium phosphate
- 4 A pharmaceutical composition as claimed in any of claims 1 to 3 wherein the ratio of the tribasic phosphate salt to the active ingredient is in the range of 1:80 to 50:1 by weight
- 5 A pharmaceutical composition as claimed in any preceding claim additionally comprising one or more fillers, binders, disintegrants or lubricants
- 6 A pharmaceutical composition for oral administration comprising (E) 7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl(methylsulfonyl)amino}pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, one or more fillers, one or more binders, one or more disintegrants, one or more lubricants and a tribasic phosphate salt in which the cation is multivalent
- 7 A pharmaceutical composition as claimed in claim 6 wherein the active ingredient is present in an amount 1 to 80% by weight of the composition
- 8 A pharmaceutical composition as claimed in claim 6 or 7 wherein the tribasic phosphate salt is present in an amount 1 to 50% by weight of the composition
- 9 A pharmaceutical composition as claimed in claim 6, 7 or 8 wherein the filler is present in an amount 30 to 90% by weight of the composition
- 10 A pharmaceutical composition as claimed in any of claims 6 to 9 wherein the binder is present in an amount 2 to 80% by weight of the composition
- 11 A pharmaceutical composition as claimed in any of claims 6 to 10 wherein the disintegrant is present in an amount 2 to 10% by weight of the composition
- 12 A pharmaceutical composition as claimed in any of claims 6 to 11 wherein the lubricant is present in an amount 0.5 to 3% by weight
- 13 A pharmaceutical composition as claimed in claim 6 comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl(methylsulfonyl)amino}pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch glycolate, butylated hydroxytoluene and magnesium stearate
- 14 A pharmaceutical composition as claimed in claim 6 comprising (E) 7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl(methylsulfonyl)amino}pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, povidone, microcrystalline cellulose, mannitol, sodium starch glycolate, butylated hydroxytoluene and magnesium stearate
- 15 A pharmaceutical composition as claimed in claim 6 comprising (E) 7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl(methylsulfonyl)amino}pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, croscopolvdone, microcrystalline cellulose, lactose and magnesium stearate
- 16 A pharmaceutical composition as claimed in claim 6 comprising (E) 7-[4-(4-fluorophenyl)-6-isopropyl-2-{methyl

71 74
A

EP 1 223 918 B1

(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient tribasic calcium phosphate povidone microcrystalline cellulose lactose sodium starch glycolate butylated hydroxytoluene and magnesium stearate

- 5 17 A pharmaceutical composition as claimed in any preceding claim wherein the active ingredient is the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid.
- 10 18 The use of a tribasic phosphate salt in which the cation is multivalent to stabilise the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof
- 15 19 The use as claimed in claim 18 wherein the tribasic phosphate salt in which the cation is multivalent is selected from tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate
- 20 20 The use as claimed in claim 18 or 19 wherein the tribasic phosphate salt in which the cation is multivalent is tribasic calcium phosphate
- 25 21 A method of producing a stabilised pharmaceutical composition which comprises incorporating a tribasic phosphate salt in which the cation is multivalent in a pharmaceutical composition containing the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof

25 Patentansprüche

- 30 1 Pharmazeutische Zusammensetzung enthaltend (E)-7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff und ein dreibasiges Phosphatsalz mit einem mehrwertigen Kation
- 35 2 Pharmazeutische Zusammensetzung nach Anspruch 1 wobei das dreibasige Phosphatsalz mit dem mehrwertigen Kation aus dreibasischem Calciumphosphat, dreibasischem Magnesiumphosphat und dreibasischem Aluminiumphosphat ausgewählt ist
- 40 3 Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2 wobei es sich bei dem dreibasischen Phosphatsalz mit mehrwertigem Kation um dreibasisches Calciumphosphat handelt
- 45 4 Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 3 wobei das Verhältnis von dreibasischem Phosphatsalz zu Wirkstoff im Bereich von 1:80 bis 1:50 (w/w) liegt
- 50 5 Pharmazeutische Zusammensetzung nach einem der vorhergehenden Ansprüche weiterhin enthaltend einen oder mehrere Füllstoffe, Bindemittel, Sprengmittel oder Gleitmittel
- 55 6 Pharmazeutische Zusammensetzung zur oralen Verabreichung enthaltend (E)-7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff, einen oder mehrere Füllstoffe, ein oder mehrere Bindemittel, ein oder mehrere Sprengmittel, ein oder mehrere Gleitmittel und ein dreibasiges Phosphatsalz mit mehrwertigem Kation
- 60 7 Pharmazeutische Zusammensetzung nach Anspruch 6 wobei der Wirkstoff in einer Menge von 1 bis 80 Gew.-% der Zusammensetzung vorliegt
- 65 8 Pharmazeutische Zusammensetzung nach Anspruch 6 oder 7 wobei das dreibasige Phosphatsalz in einer Menge von 1 bis 50 Gew.-% der Zusammensetzung vorliegt
- 70 9 Pharmazeutische Zusammensetzung nach Anspruch 6, 7 oder 8 wobei der Füllstoff in einer Menge von 30 bis 90 Gew.-% der Zusammensetzung vorliegt
- 75 10 Pharmazeutische Zusammensetzung nach einem der Ansprüche 6 bis 9 wobei das Bindemittel in einer Menge

von 2 bis 90 Gew % der Zusammensetzung vorliegt

11 Pharmazeutische Zusammensetzung nach einem der Ansprüche 6 bis 10 wobei das Sprengmittel in einer Menge von 2 bis 10 Gew % der Zusammensetzung vorliegt

12 Pharmazeutische Zusammensetzung nach einem der Ansprüche 6 bis 11 wobei das Gleitmittel in einer Menge von 0,5 bis 3 Gew % vorliegt

13 Pharmazeutische Zusammensetzung nach Anspruch 8 enthaltend (E) 7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff dreibasiges Calciumphosphat mikrokristalline Cellulose Lactose Natriumstärkeglycolat Butylhydroxytoluol und Magnesiumstearat

14 Pharmazeutische Zusammensetzung nach Anspruch 8 enthaltend (E) 7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff dreibasiges Calciumphosphat Povidon mikrokristalline Cellulose Mannit Natriumstärkeglycolat, Butylhydroxytoluol und Magnesiumstearat

15 Pharmazeutische Zusammensetzung nach Anspruch 8 enthaltend (E) 7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff dreibasiges Calciumphosphat Crospovidon mikrokristalline Cellulose Lactose und Magnesiumstearat

16 Pharmazeutische Zusammensetzung nach Anspruch 8 enthaltend (E) 7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon als Wirkstoff dreibasiges Calciumphosphat Povidon mikrokristalline Cellulose Lactose Natriumstärkeglycolat, Butylhydroxytoluol und Magnesiumstearat

17 Pharmazeutische Zusammensetzung nach einem der vorhergehenden Ansprüche wobei es sich bei dem Wirkstoff um das Calciumsalz von (E)-7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure handelt

18 Verwendung eines dreibasigen Phosphatsalzes mit mehrwertigem Kation zur Stabilisierung der Verbindung (E)-7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder eines pharmazeutisch unbedenklichen Salzes davon

19 Verwendung nach Anspruch 18 wobei das dreibasige Phosphatsalz mit mehrwertigem Kation aus dreibasigem Calciumphosphat dreibasigem Magnesiumphosphat und dreibasigem Aluminiumphosphat ausgewählt ist

20 Verwendung nach Anspruch 18 oder 19 wobei es sich bei dem dreibasigen Phosphatsalz mit mehrwertigem Kation um dreibasiges Calciumphosphat handelt

21 Verfahren zur Herstellung einer stabilisierten pharmazeutischen Zusammensetzung bei dem man ein dreibasiges Phosphatsalz mit mehrwertigem Kation in eine pharmazeutische Zusammensetzung die die Verbindung (E)-7-[4-(4-Fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-ensäure oder ein pharmazeutisch unbedenkliches Salz davon enthält einarbeitet

Revendications

1 Composition pharmaceutique comprenant de l'acide (E)-7-[4-(4-fluorophényl)-6-isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, et un sel orthophosphate neutre dans lequel le cation est polyvalent

2 Composition pharmaceutique selon la revendication 1 dans laquelle le sel orthophosphate neutre dans lequel le cation est polyvalent est choisi parmi le phosphate tricalcique le phosphate trimagnésique et le phosphate trialuminiumique

73
10/16

- 3 Composition pharmaceutique selon la revendication 1 ou 2 dans laquelle le sel orthophosphate neutre dans lequel le cation est polyvalent est le phosphate tricalcique
- 4 Composition pharmaceutique selon l'une quelconque des revendications 1 à 3 dans laquelle le rapport du sel orthophosphate neutre au principe actif est dans la gamme de 1/80 à 50/1 en poids
- 5 Composition pharmaceutique selon l'une quelconque des revendications précédentes comprenant en plus une ou plusieurs charges et un ou plusieurs liants déliants ou lubrifiants
- 6 Composition pharmaceutique pour administration orale comprenant de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, une ou plusieurs charges, un ou plusieurs liants, un ou plusieurs déliants, un ou plusieurs lubrifiants et un sel orthophosphate neutre dans lequel le cation est polyvalent
- 7 Composition pharmaceutique selon la revendication 6 dans laquelle le principe actif est présent à raison de 1 à 80% en poids de la composition
- 8 Composition pharmaceutique selon la revendication 6 ou 7 dans laquelle le sel orthophosphate neutre est présent à raison de 1 à 50% en poids de la composition
- 9 Composition pharmaceutique selon la revendication 6, 7 ou 8 dans laquelle la charge est présente à raison de 30 à 90% en poids de la composition
- 10 Composition pharmaceutique selon l'une quelconque des revendications 6 à 9 dans laquelle le liant est présent à raison de 2 à 90% en poids de la composition
- 11 Composition pharmaceutique selon l'une quelconque des revendications 6 à 10 dans laquelle le déliant est présent à raison de 2 à 10% en poids de la composition
- 12 Composition pharmaceutique selon l'une quelconque des revendications 6 à 11 dans laquelle le lubrifiant est présent à raison de 0,5 à 3% en poids
- 13 Composition pharmaceutique selon la revendication 6 comprenant de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, du phosphate tricalcique, de la cellulose microcristalline, du lactose, de l'amidon-glycolate de sodium, de l'hydroxytoluène butylé et du stéarate de magnésium
- 14 Composition pharmaceutique selon la revendication 6 comprenant de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, du phosphate tricalcique, de la povidone, de la cellulose microcristalline, du mannitol, de l'amidon-glycolate de sodium, de l'hydroxytoluène butylé et du stéarate de magnésium
- 15 Composition pharmaceutique selon la revendication 6 comprenant de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, du phosphate tricalcique, de la croscopvidone, de la cellulose microcristalline, du lactose et du stéarate de magnésium
- 16 Composition pharmaceutique selon la revendication 6 comprenant de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de cet acide comme principe actif, du phosphate tricalcique, de la povidone, de la cellulose microcristalline, du lactose, de l'amidon-glycolate de sodium, de l'hydroxytoluène butylé et du stéarate de magnésium
- 17 Composition pharmaceutique selon l'une quelconque des revendications précédentes dans laquelle le principe actif est le sel de calcium de l'acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-énoïque

74

H

EP 1 223 918 B1

- 18 Utilisation d'un sel orthophosphate neutre dans lequel le cation est polyvalent pour stabiliser le composé acide
(E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept
6-énoïque ou un sel pharmaceutiquement acceptable de ce composé
- 5 19 Utilisation selon la revendication 18 dans laquelle le sel orthophosphate neutre dans lequel le cation est polyvalent
est choisi parmi le phosphate tricalcique, le phosphate trimagnésique et le phosphate trialuminique
- 20 Utilisation selon la revendication 18 ou 19 dans laquelle le sel orthophosphate neutre dans lequel le cation est
polyvalent est le phosphate tricalcique
- 10 21 Procédé de production d'une composition pharmaceutique stabilisée qui comprend l'incorporation d'un sel ortho
phosphate neutre dans lequel le cation est polyvalent dans une composition pharmaceutique contenant le composé
acide (E) 7-[4-(4-fluorophényl)-6 isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihy
droxyhept-6-énoïque ou un sel pharmaceutiquement acceptable de ce composé
- 15

20

25

30

35

40

45

50

55